Scottish pharma enterprise closes Italian acquisition

A SCOTTISH specialty pharma enterprise primarily based within the Scottish Borders has closed its acquisition of a Milan-based agency.

The acquisition of Velit Biopharma by Kelso Pharma was first introduced on 13 November 2023.

It is step one for Kelso in its European growth technique and Velit is now a part of the Kelso group of firms which additionally contains Glasgow-based Stirling Anglian Prescribed drugs (SAP).

Velit specialises in growing and registering “laborious to make” medicines which it then makes out there to sufferers via partnerships with pharma firms and distributors throughout Europe, Asia and the Center East.

It has greater than 100 partnerships in 48 areas and nations protecting 167 merchandise, with greater than 15 additional launches with current companions deliberate for 2024 onwards.

The Kelso Pharma board members: Sam Grey, Apposite; Christian Schenk, Apposite, Tom Stratford, CEO; Gordon Cameron OBE, Chairman; Allan Watson, CFO.

Velit’s therapeutic concentrate on gastroenterology, dermatology and ladies’s well being enhances Kelso’s current portfolio of medicines.

Velit’s portfolio and pipeline additionally options merchandise centered on oncology and ophthalmology, additional extending Kelso’s therapeutic vary, with a variety of merchandise out there to be commercialised within the UK via Kelso’s current infrastructure.

Kelso Pharma is targeted on bringing revolutionary, worth added, specialty medicines to the European healthcare markets, offering medicines that enhance the lives of sufferers in a cheap and moral method.

The corporate is rising via a mix of firm and product acquisitions, partnerships and natural development and the Velit transaction is a vital stepping stone for Kelso Pharma’s ambition to develop into the remainder of Europe.

Since its inception in 2020, Kelso Pharma has taken a variety of steps to develop the enterprise in an efficient and sustainable method, positively impacting its companions and sufferers.

The acquisition of Glasgow-based SAP in January 2022 supplied a brand new UK platform and a possible springboard for future gross sales development for the enterprise.

SAP’s model portfolio already has 4 medicines within the UK healthcare market, together with Acepiro (Acetylcysteine) which was launched in early 2023 and is used to loosen mucus and to ease coughing up in circumstances of respiratory ailments with viscous mucus.

In October final 12 months, Kelso introduced the acquisition of two UK accredited dermatology merchandise from German pharma firm, Dermapharm.

Dr Tom Stratford, Chief Government of Kelso Pharma mentioned: “We welcome the Velit workforce to Kelso Pharma.

“I’m assured that, collectively, we are able to construct on this deal as a springboard for our European growth whereas persevering with to fulfill the wants of our sufferers and clinicians.”

Dr Nicola Travierso of Velit mentioned: “We’re delighted to change into a part of the Kelso Pharma household and stay up for serving to Tom and the workforce develop the enterprise collectively.”